Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis

@article{Schouwenburg2013ImmunogenicityOA,
  title={Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis},
  author={Pauline A. van Schouwenburg and Theo Rispens and Gerrit Jan J Wolbink},
  journal={Nature Reviews Rheumatology},
  year={2013},
  volume={9},
  pages={164-172}
}
Currently, five anti-TNF biologic agents are approved for the treatment of rheumatoid arthritis (RA): adalimumab, infliximab, etanercept, golimumab and certolizumab pegol. Formation of anti-drug antibodies (ADA) has been associated with all five agents. In the case of adalimumab and infliximab, immunogenicity is strongly linked to subtherapeutic serum drug levels and a lack of clinical response, but for the other three agents, data on immunogenicity are scarce, suggesting that further research… CONTINUE READING
Highly Influential
This paper has highly influenced 12 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
Recent Discussions
This paper has been referenced on Twitter 14 times over the past 90 days. VIEW TWEETS
112 Citations
104 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 112 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 104 references

Differential effect of drug interference in immunogenicity assays

  • Hart, H M.
  • J. Immunol. Methods 372,
  • 2011

Similar Papers

Loading similar papers…